All Stories

  1. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

    Article • Journal of Medical Economics, January 2019, Taylor & Francis

    David Hutton

  2. Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over A Ten-Year Period

    Article • Health Affairs, June 2014, Health Affairs

    David Hutton